Daneshvar cofounded Pioneera Biosciences in 2023, focusing on advanced cell and gene therapies. It offers three therapies: the CAR-T for Multiple Myeloma, the Allogenic Adoptive T Cell for preventing CMV infection in post-transplantation patients, and the Allogenic CAR-NK, which is based on mRNA-LNP and indicated for CD19-positive B-Cell malignancies. The Allogenic T Cell Therapy for transplantation patients is advancing through Phase 2 clinical trials, while the CAR-T and Allogenic CAR-NK cell therapies are poised to enter Phase 1 trials. The company has secured Investigational New Drug status with the Department of Health – Abu Dhabi. It has filed provisional patents and is in the process of filling PCT applications.